Nanoparticle-based drug delivery for glioma treatment
Innovative nanoparticle formulation delivering drugs directly to glioma brain tumors, potentially improving treatment outcomes for patients with aggressive pediatric brain cancer.
Overview
The nanoparticle-based drug delivery system presents a novel approach to treating gliomas, particularly in pediatric brain tumors like Diffuse Large B-cell Lymphoma (DLGNT). This innovative system uses nanoparticles to deliver drug cargo directly to the tumor site, ensuring high concentrations in the tumor and minimizing exposure to healthy brain tissue. This targeted delivery method holds the potential to significantly enhance therapeutic efficacy and patient survival outcomes.
Technical specifications
- Nanoparticle formulation: Designed to selectively target glioma stem cells, enhancing drug concentration at the tumor site.
- Drug delivery: Utilizes intraperitoneal (I.p.) administration to effectively transport the drug-nanoparticle conjugate.
- Selective targeting: Preliminary data shows high localization of the drug in tumor tissue with reduced impact on normal brain cells.
- Therapeutic potential: Aims to reduce tumor burden and improve survival rates in aggressive pediatric brain tumor models.
Technology readiness level
This technology is currently at Technology Readiness Level 3, indicating that it is in the early stages of development with demonstrated proof of concept in laboratory settings. Further validation studies are planned to refine dosing and scheduling, with the goal of advancing to clinical trials.
About Memorial Sloan-Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a large, independent academic medical and research institution devoted exclusively to cancer, combining comprehensive patient care, scientific discovery, and education. Its research enterprise links the Sloan Kettering Institute and Memorial Hospital, allowing basic, translational, and clinical teams to work within one cancer-focused system while supporting clinical trials and industry collaboration. Corporate partners can engage through shared research infrastructure, specialized clinical capabilities, and dedicated partnership channels. Research receives support from the National Institutes of Health, including the National Cancer Institute, alongside philanthropic and industry funding. The Office of Entrepreneurship and Commercialization manages intellectual property, licensing, startup formation, and business development.
delivered to your inbox.